

# Access Services by Bayer™

## for VITRAKVI® (larotrectinib)

PHONE



**1-800-288-8374**

9:00 AM–6:00 PM ET, Monday–Friday

Call Access Services by Bayer for:

- Program questions
- Co-pay questions
- Information for additional financial support

FAX



**1-800-390-1826**

VISIT



**VITRAKVI-US.com**

Information provided in this resource is for informational purposes only and does not guarantee that codes will be appropriate or that coverage and reimbursement will result. Customers should consult with their payers for all relevant coverage, coding, and reimbursement requirements. It is the sole responsibility of the provider to select proper codes and ensure the accuracy of all claims used in seeking reimbursement. Neither this resource nor Access Services by Bayer™ is intended as legal advice or as a substitute for a provider's independent professional judgment.

Please see full Important Safety Information on page 3,  
and click here for full [Prescribing Information](#).

## VITRAKVI® (larotrectinib) Sample Letter of Medical Necessity



[DATE]

[NAME OF CONTACT AT PAYER]  
[PAYER COMPANY NAME]  
[ADDRESS]

Insured: [NAME OF INSURED]  
Patient: [NAME OF PATIENT (if different)]  
Patient Date of Birth: [MM/DD/YYYY]  
Policy Number: [NUMBER]  
Group Number: [NUMBER]

Dear [NAME OF CONTACT AT PAYER],

I am writing on behalf of my patient, [NAME OF PATIENT], to request that [PAYER COMPANY NAME] approve coverage for VITRAKVI®. VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that:

- have a neurotrophic receptor tyrosine kinase (*NTRK*) gene fusion without a known acquired resistance mutation,
- are metastatic or where surgical resection is likely to result in severe morbidity, and
- have no satisfactory alternative treatments or that have progressed following treatment.

Select patients for therapy based on an FDA-approved test.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. This letter documents the medical necessity for use of VITRAKVI by my patient and provides information about [NAME OF PATIENT]'s medical history and treatment, *NTRK* gene fusion diagnostic test results, and a copy of the VITRAKVI Prescribing Information.

[NAME OF PATIENT] is [a/an] [AGE]-year-old [male/female] with a diagnosis of [PATIENT DIAGNOSIS] as of [DATE OF DIAGNOSIS]. [NAME OF PATIENT] has been in my care for [PATIENT DIAGNOSIS] since [DATE]. [Provide a brief discussion of patient's relevant medical history, condition/symptoms, *NTRK* gene fusion diagnostic test results, and therapy to date, including other treatments attempted and results].

Based on the above information, VITRAKVI is indicated and medically necessary for [NAME OF PATIENT]'s treatment. If you have any questions, please contact me at [PHYSICIAN TELEPHONE NUMBER]. Thank you in advance for your immediate attention to this request.

Sincerely,

[PHYSICIAN NAME]  
[PRACTICE NAME]

Attachments: [original claim form, copy of denial or explanation of benefits (if applicable), copy of patient's insurance card, VITRAKVI Prescribing Information, FDA approval letter, larotrectinib primary publication, etc]



Please see full Important Safety Information on page 3,  
and click here for full [Prescribing Information](#).

# Indication and Important Safety Information

## Indication

VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that:

- have a neurotrophic receptor tyrosine kinase (*NTRK*) gene fusion without a known acquired resistance mutation,
- are metastatic or where surgical resection is likely to result in severe morbidity, and
- have no satisfactory alternative treatments or that have progressed following treatment.

Select patients for therapy based on an FDA-approved test.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

## Important Safety Information

**Central Nervous System Effects:** Central nervous system (CNS) adverse reactions occurred in patients receiving VITRAKVI, including dizziness, cognitive impairment, mood disorders, and sleep disturbances.

In patients who received VITRAKVI, all grades CNS effects including cognitive impairment, mood disorders, dizziness and sleep disorders were observed in 42% with Grades 3-4 in 3.9% of patients.

Cognitive impairment occurred in 11% of patients. The median time to onset of cognitive impairment was 5.6 months (range: 2 days to 41 months). Cognitive impairment occurring in  $\geq 1\%$  of patients included memory impairment (3.6%), confusional state (2.9%), disturbance in attention (2.9%), delirium (2.2%), cognitive disorders (1.4%), and Grade 3 cognitive adverse reactions occurred in 2.5% of patients. Among the 30 patients with cognitive impairment, 7% required a dose modification and 20% required dose interruption.

Mood disorders occurred in 14% of patients. The median time to onset of mood disorders was 3.9 months (range: 1 day to 40.5 months). Mood disorders occurring in  $\geq 1\%$  of patients included anxiety (5%), depression (3.9%), agitation (2.9%), and irritability (2.9%). Grade 3 mood disorders occurred in 0.4% of patients.

Dizziness occurred in 27% of patients, and Grade 3 dizziness occurred in 1.1% of patients. Among the 74 patients who experienced dizziness, 5% of patients required a dose modification and 5% required dose interruption.

Sleep disturbances occurred in 10% of patients. Sleep disturbances included insomnia (7%), somnolence (2.5%), and sleep disorder (0.4%). There were no Grade 3-4 sleep disturbances. Among the 28 patients who experienced sleep disturbances, 1 patient each (3.6%) required a dose modification or dose interruption.

Advise patients and caretakers of these risks with VITRAKVI. Advise patients not to drive or operate hazardous machinery if they are experiencing neurologic adverse reactions. Withhold or permanently discontinue VITRAKVI based on the severity. If withheld, modify the VITRAKVI dosage when resumed.

**Skeletal Fractures:** Among 187 adult patients who received VITRAKVI across clinical trials, fractures were reported in 7% and among 92 pediatric patients, fractures were reported in 9% (N=279; 8%). Median time to fracture was 11.6 months (range 0.9 to 45.8 months) in patients followed per fracture. Fractures of the femur, hip or acetabulum were reported in 4 patients (3 adult, 1 pediatric). Most fractures were associated with minimal or moderate trauma. Some fractures were associated with radiologic abnormalities suggestive of local tumor involvement. VITRAKVI treatment was interrupted due to fracture in 1.4% patients.

Promptly evaluate patients with signs or symptoms of potential fracture (e.g., pain, changes in mobility, deformity). There are no data on the effects of VITRAKVI on healing of known fractures or risk of future fractures.

**Hepatotoxicity:** In patients who received VITRAKVI, increased AST of any grade occurred in 52% of patients and increased ALT of any grade occurred in 45%. Grade 3-4 increased AST or ALT occurred in 3.1% and 2.5% of patients, respectively. The median time to onset of increased AST was 2.1 months (range: 1 day to 4.3 years). The median time to onset of increased ALT was 2.3 months (range: 1 day to 4.2 years). Increased AST and ALT leading to dose modifications occurred in 1.4% and 2.2% of patients, respectively. Increased AST or ALT led to permanent discontinuation in 3 (1.1%) of patients.

Monitor liver tests, including ALT and AST, every 2 weeks during the first month of treatment, then monthly thereafter, and as clinically indicated. Withhold or permanently discontinue VITRAKVI based on the severity. If withheld, modify the VITRAKVI dosage when resumed.

**Embryo-Fetal Toxicity:** VITRAKVI can cause fetal harm when administered to a pregnant woman. Larotrectinib resulted in malformations in rats and rabbits at maternal exposures that were approximately 11- and 0.7-times, respectively, those observed at the clinical dose of 100 mg twice daily. Advise women of the potential risk to a fetus. Advise females of reproductive potential to use an effective method of contraception during treatment and for 1 week after the final dose of VITRAKVI.

**Most Common Adverse Reactions ( $\geq 20\%$ ):** The most common adverse reactions ( $\geq 20\%$ ), including laboratory abnormalities, were: increased AST (52%), increased ALT (45%), anemia (42%), musculoskeletal pain (42%), fatigue (36%), hypoalbuminemia (36%), neutropenia (36%), increased alkaline phosphatase (34%), cough (32%), leukopenia (28%), constipation (27%), diarrhea (27%), dizziness (27%), hypocalcemia (25%), nausea (25%), vomiting (25%), pyrexia (24%), lymphopenia (22%) and abdominal pain (21%).

**Drug Interactions:** Avoid coadministration of VITRAKVI with strong CYP3A4 inhibitors (including grapefruit or grapefruit juice), strong CYP3A4 inducers (including St. John's wort), or sensitive CYP3A4 substrates. If coadministration of strong CYP3A4 inhibitors or inducers cannot be avoided, modify the VITRAKVI dose as recommended. If coadministration of sensitive CYP3A4 substrates cannot be avoided, monitor patients for increased adverse reactions of these drugs.

**Lactation:** Advise women not to breastfeed during treatment with VITRAKVI and for 1 week after the final dose.

Please click here for full [Prescribing Information](#).



© 2021 Bayer. All rights reserved. Bayer, the Bayer Cross, and VITRAKVI are registered trademarks of Bayer, and Access Services by Bayer is a trademark of Bayer. MAC-VIT-US-0165-1 04/21

